Cargando…

Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials

INTRODUCTION: Low-dose aspirin or clopidogrel, statins, renin–angiotensin system inhibitors, and beta blockers are the cornerstone therapy for cardiovascular prevention in patients with coronary heart disease. Using only single-antiplatelet therapy for secondary prevention in patients with stable co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Debasu, Zenaw, Kedir, Hanan Muzeyin, Tadesse, Tamrat Assefa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480577/ https://www.ncbi.nlm.nih.gov/pubmed/36118183 http://dx.doi.org/10.2147/IJGM.S383485

Ejemplares similares

Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
por: Ferrara, Pietro, et al.
Publicado: (2021)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022)

Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022)

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019)

Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review
por: Kedir, Hanan Muzeyin, et al.
Publicado: (2021)

Determinants of Reduced Antiplatelet Effect of Aspirin in Patients with Stable Coronary Artery Disease
por: Larsen, Sanne Bøjet, et al.
Publicado: (2015)

Rivaroxaban plus aspirin vs. dual antiplatelet therapy in endovascular treatment in peripheral artery disease and analysis of medication utilization of different lesioned vascular regions
por: Huo, SiYan, et al.
Publicado: (2023)

The lack of aspirin resistance in patients with coronary artery disease
por: Homoródi, Nóra, et al.
Publicado: (2016)

Venous Thromboembolism Risk and Thromboprophylaxis Assessment in Surgical Patients Based on Caprini Risk Assessment Model
por: Tadesse, Tamrat Assefa, et al.
Publicado: (2020)

Incidence of thromboembolism and thromboprophylaxis in medical patients admitted to specialized hospital in Ethiopia using Padua prediction score
por: Asmamaw, Mulugeta, et al.
Publicado: (2022)

Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study
por: Jurk, Kerstin, et al.
Publicado: (2022)

Description of 3 Cases in Vietnam of Aspirin Desensitization in Patients With Coronary Artery Disease and Coexisting Aspirin Hypersensitivity
por: Van Nguyen, Dinh, et al.
Publicado: (2012)

Low-dose aspirin and rivaroxaban combination therapy to overcome aspirin non-sensitivity in patients with vascular disease
por: Khan, Hamzah, et al.
Publicado: (2022)

High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)
por: Pettersen, Alf-Åge R., et al.
Publicado: (2012)

Vascular protective effect of aspirin and rivaroxaban upon endothelial denudation of the mouse carotid artery
por: Mastenbroek, T. G., et al.
Publicado: (2020)

Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease
por: Larsen, Sanne Bøjet, et al.
Publicado: (2017)

Association between Multiplate-measured aspirin resistance and vitamin D deficiency in stable coronary artery disease
por: Surmen, Semih, et al.
Publicado: (2021)

Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis
por: Wang, Han, et al.
Publicado: (2022)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Coronary Artery Disease and Aspirin Intolerance: Background and Insights on Current Management
por: Thakker, Ravi A., et al.
Publicado: (2022)

Aspirin plus clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: angiographic and clinical results of a randomized study
por: Dalmau, Maria J, et al.
Publicado: (2015)

Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios
por: McClure, Graham R., et al.
Publicado: (2019)

Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study
por: Zekri-Nechar, Khaoula, et al.
Publicado: (2022)

Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease
por: Liu, Xian-Feng, et al.
Publicado: (2013)

Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease
por: Zhang, JW, et al.
Publicado: (2017)

Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease
por: Pedersen, Oliver Buchhave, et al.
Publicado: (2021)

Aspirin Versus Clopidogrel Monotherapy for the Treatment of Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis
por: Yuan, Jun, et al.
Publicado: (2019)

Comparison of Midterm Outcomes Associated With Aspirin and Ticagrelor vs Aspirin Monotherapy After Coronary Artery Bypass Grafting for Acute Coronary Syndrome
por: Björklund, Erik, et al.
Publicado: (2021)

Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing
por: Willemsen, Laura M., et al.
Publicado: (2021)

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting
por: Sharma, Rakesh K, et al.
Publicado: (2009)

Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020)

vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease
por: Warlo, Ellen M. K., et al.
Publicado: (2017)

Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients
por: Schwartz, Kenneth A, et al.
Publicado: (2008)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
por: Moll, Frans, et al.
Publicado: (2018)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
por: Qu, Jianyu, et al.
Publicado: (2021)

The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]
por: Kulik, Alexander, et al.
Publicado: (2005)

Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease
por: Gibler, W. Brian
Publicado: (2018)

Feel Free to Use Aspirin before Coronary Artery Bypass Surgery
por: Ahn, Jung-Min
Publicado: (2019)

Evaluation of high-dose aspirin elimination in the treatment of Kawasaki disease in the incidence of coronary artery aneurysm
por: Sanati, Farima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_04ddvequrtbmki3ueuea8aishr